Hostname: page-component-586b7cd67f-dlnhk Total loading time: 0 Render date: 2024-11-25T16:35:11.546Z Has data issue: false hasContentIssue false
  • English
  • Français

The new genetics in psychiatry

Published online by Cambridge University Press:  02 January 2018

Eleanor Feldman
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Advances in the understanding of the genetic causes of some neuropsychiatric disorders are having an impact on clinical practice as direct mutation analysis becomes possible. Mutation analysis is now available in UK Health Service diagnostic laboratories for Huntington's disease (HD) and the fragile X syndrome (FRAXA). Psychiatrists need to be familiar with issues surrounding presymptomatic and diagnostic testing in HD and diagnostic and carrier testing in FRAXA. They may be asked to assist clinical geneticists in the assessment of candidates for HD presymptomatic testing and a suggested mode of assessment is described here. The procedure for HD will provide the model for use with other familial neuropsychiatric disorders of late onset, notably familial Alzheimer's disease (FAD). Testing for FAD is already possible in conjunction with research laboratories in the few families where a mutation has been discovered and we shall have more tests for FAD within a few years.

Type
Research Article
Information
Advances in Psychiatric Treatment , Volume 1 , Issue 4 , March 1995 , pp. 109 - 115
Copyright
Copyright © The Royal College of Psychiatrists 1995 

References

Bloch, M., Adam, S., Wiggins, S. et al (1992) Predictive testing for Huntington's disease in Canada: the experience of those receiving an increased risk. American Journal of Medical Genetics, 42, 499–507.CrossRefGoogle ScholarPubMed
Brunner, H. G., Nelen, M., Breakefield, X. O. et al (1993) Abnormal behaviour associated with a point mutation in the structural gene for monoamine oxidase A. Science, 262, 578–580.Google Scholar
Caine, E. D. & Shoulson, I. (1983) Psychiatric syndromes in Huntington's disease. American Journal of Psychiatry, 140, 728–733.Google ScholarPubMed
Clark, R. F. & Goate, A. M. (1993) Molecular genetics of Alzheimer's disease. Archives of Neurology, 50, 1164–1172.Google Scholar
Corder, E. H., Saunders, A. M., Strittmatter, W. J. et al (1993) Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science, 261, 921–923.CrossRefGoogle ScholarPubMed
Craufurd, D. & Tyler, A. on behalf of the UK Huntington's Prediction Consortium (1992) Predictive testing for Huntington's disease: protocol of the UK Huntington's Prediction Consortium. Journal of Medical Genetics, 29, 915–918.CrossRefGoogle ScholarPubMed
De Vries, L. B. A., Halley, D. J. J., Oostra, B. A. et al (1994) The fragile-X syndrome: a growing gene causing familial intellectual disability. Journal of Intellectual Disability Research, 38, 1–8.Google Scholar
Diamond, R., White, R. F., Myers, R. H. et al (1992) Evidence of presymptomatic cognitive decline in Huntington's disease. Journal of Clinical and Experimental Neuropsychology, 14, 961–975.Google Scholar
Duyao, M., Ambrose, C., Myers, R. et al (1993) Trinucleotide repeat length instability and age of onset in Huntington's disease. Nature Genetics, 4, 387–392.Google Scholar
Folstein, S. E., Abbott, M. H., Chase, G. A. et al (1983) The association of affective disorder with Huntington's disease in a case series and in families. Psychological Medicine, 13, 537–542.Google Scholar
Folstein, S. E., Leigh, J., Parhad, I. M. et al (1986). The diagnosis of Huntington's disease. Neurology, 36, 1279–1283.Google Scholar
Ford, M. F. (1986) Treatment of depression in Huntington's disease with monoamine oxidase inhibitors. British Journal of Psychiatry, 149, 654–656.Google Scholar
Glass, I. A. (1991) X-linked mental retardation. Journal of Medical Genetics, 28, 361–71.Google Scholar
Goate, A., Chartier-Harlin, M. C., Mullan, M. et al (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature, 349, 704–706.Google Scholar
Gusella, J. F., Wexler, N. S., Conneally, P. M. et al (1983) A polymorphic DNA marker genetically linked to Huntington's disease. Nature, 306, 234–238.Google Scholar
Harper, P. S. (1988) Practical Genetic Counselling (3rd edn). Butterworth-Heinemann.Google Scholar
Hayden, M. R. (1981) Huntington's Chorea. New York: Springer-Verlag.CrossRefGoogle ScholarPubMed
Huggins, M., Bloch, M., Wiggins, S. et al (1992) Predictive testing for Huntington's disease in Canada: adverse effects and unexpected results in those receiving a decreased risk. American Journal of Medical Genetics, 42, 508–515.Google Scholar
Huntington's Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971–983.Google Scholar
Jouet, M., Rosenthal, A., Armstrong, G. et al (1994) X-linked spastic paraplegia (SPG1), MASA syndrome and X-linked hydrocephalus result from mutations in the L1 gene. Nature Genetics, 7, 402–407.Google Scholar
Knight, S. J. L., Flannery, A. V., Hirst, M. C. et al (1993) Trinucleotide repeat amplification and hypermethylation of a CpG Island in FRAXE mental retardation. Cell, 74, 127–134.Google Scholar
McGuffin, P., Owen, M., O'Donovan, M. et al (1994) Seminars in Psychiatric Genetics. London: Gaskell.Google Scholar
Owen, M., Liddell, M. & McGuffin, P. (1994) Alzheimer's disease. An association with apolipoprotein E4 may help unlock the puzzle. British Medical Journal, 308, 672–673.Google Scholar
Pflanz, S., Besson, J. A. O., Ebmeier, K. P. et al (1991) The clinical manifestation of mental disorder in Huntington's disease: a retrospective case record study of disease progression. Acta Psychiatrica Scandanavica, 83, 53–60.Google Scholar
Rousseau, F., Heitz, D., Biancalana, V. et al (1991) Direct diagnosis by DNA analysis of the fragile X syndrome of mental retardation. New England Journal of Medicine, 325, 1673–1681.CrossRefGoogle ScholarPubMed
Schoenfeld, M., Myers, R. H., Cupples, A. et al (1984) Increased rate of suicide among patients with Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 47, 1283–1287.Google Scholar
Schwartz, C. E. (1993) Invited editorial: X-linked mental retardation: in pursuit of a gene map. American Journal of Human Genetics, 52, 1025–1031.Google Scholar
Turk, J. (1992) The fragile X syndrome: on the way to a behavioural phenotype. British Journal of Psychiatry, 160, 24–35.Google Scholar
Tyler, A., Morris, M., Lazarou, L. et al (1992) Presymptomatic testing for Huntington's disease in Wales 1987–90. British Journal of Psychiatry, 161, 481–488.CrossRefGoogle ScholarPubMed
Verkerk, A. J. M. H., Pieretti, M., Sutcliffe, J. S. et al (1991) Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region length variation in fragile X syndrome. Cell, 65, 905–914.Google Scholar
Young, I. D. (1993) Diagnosing fragile X syndrome. Lancet, 342, 1004–1005.CrossRefGoogle ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.